BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer. For additional information on BriaCell, please visit our website: http://briacell.com/

Prevail Partners

BriaCell Therapeutics Corp.

Additional survival updates and clinical data sets on BriaCell's entire Phase 2 study cohort will be presented at the San Antonio Breast Cancer Symposium® on December 6th and 7th, 2023. https://bit.ly/3uE9n0q

Dr. William V. Williams, President and CEO of BriaCell, emphasizes importance of the new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. Learn more: https://bit.ly/3uE9n0q

After only 3 cycles, the patient in BriaCell's Phase 2 study of the Bria-IMT™ combination regimen experienced a remarkable improvement of eye-bulging “proptosis” caused by an orbital metastatic #breastcancer tumor behind the eye. Find more information: https://bit.ly/3uE9n0q

Carmen Calfa, M.D., Clinical Research Lead for the breast site disease group at the University of Miami Miller School of Medicine, Co-Director of the Cancer Survivorship Program at Sylvester Comprehensive Cancer Center, and Principal Clinical Investigator of the Phase 2 Bria-IMT™ study highlights BriaCell's new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. https://bit.ly/3uE9n0q

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. The patient, who had previously failed all available therapies, had cancer behind the eye, causing proptosis (eye-bulging) and significant pain that were both resolved with BriaCell's treatment. For additional details, visit: https://bit.ly/3uE9n0q

Bria-IMT™ and Bria-OTS™ show great potential as targeted #immunotherapies in our ongoing battle against #breastcancer. For more information, visit: https://bit.ly/47o2fE3

Domain Not Resolving

Euro

HSTS

DNSSEC

CloudFront

Fastly

Amazon Mumbai Region

Amazon Paris Region

Amazon Stockholm Region

Chief Medical Officer

Giuseppe Priore

Controller

Anthony Passante

Member Board of Directors

Jane Gross

Clinical Operations Manager

Marcela Salgado

Healthcare

Blaise Bayer

Founder

Charles Wiseman MD

Farrah Dean

Head of Quality Assurance

Lynn Frederick

Business Management

Miguel Lopez-Lago

Clinical Scientist

Mingjin Chang

Gadi Levin

William Williams

President and CEO

Charles Wiseman

Cofounder and Director

Greater New York Area Companies that Exited

Medical Companies With More Than 10 Employees (Top 10K)

Therapeutics Companies With Fewer Than 1000 Employees (Top 10K)

United States Medical Public Companies

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

The company's patented immunotherapy Bria-IMT™ is developed from a breast cancer cell line is an immunotherapy approach that directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. It induces an antitumor response both indirectly and directly by stimulating the immune system which collectively boosts the body’s response. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in a combination with retifanlimab and epacadostat. The company is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for advanced breast cancer.

It is founded in New York, New York in 2004.

Post-IPO Equity - BriaCell Therapeutics

New York

United States

North America

BriaCell Therapeutics

BriaCell Therapeutics Announces $5 Million Offering

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study

BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Canada

Ukraine

Europe

India

Asia

Kite Pharma is a biopharmaceutical company focused on the development and commercialization of cancer immunotherapy products.

Kite Pharma

Genentech is a leading biotechnology company known for its innovative therapies in oncology, immunology, and other disease areas.

Genentech

Amgen is a multinational biopharmaceutical company known for its innovative biologic therapies in various therapeutic areas, including oncology.

Amgen

PDS Biotechnology is a clinical-stage immunotherapy company focused on developing cancer vaccines and immunotherapies.

PDS Biotechnology

Heat Biologics is a biopharmaceutical company focused on the development of immunotherapies for a wide range of cancers.

Heat Biologics Inc

DiaCarta is a molecular diagnostics company that develops and commercializes innovative oncology testing solutions.

DiaCarta

Mission Bio is a life sciences company focused on developing and commercializing single-cell genomics solutions for cancer research and treatment.

Mission Bio

Quadrants Scientific is a biotechnology company specializing in the development and commercialization of innovative scientific tools and technologies for cancer research.

Quadrants Scientific

BriaCell Therapeutics Corp. is a Phase 3 biotechnology company developing novel cellular immunotherapies to transform cancer care. Its lead drug candidate, Bria-IMT™, is designed to treat advanced metastatic breast cancer patients who did not respond to chemotherapies. The company is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 30, 2024 1:02 PM	28a6360f
crunchbase profile	general	Oct 30, 2024 1:34 PM	1d676a16
li profile	general	Feb 7, 2024 4:33 PM	9b92aaba
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	dc4db1d5
peers	general	Feb 7, 2024 4:33 PM	e1b51a77
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BCT

COM:BRIACELL

BriaCell Therapeutics Corp.

Last Close

1.09

22/11 20:59

Market Cap

24.87M

Beta: -

Volume Today

102.31K

Avg: -